Is Drostanolone Propionate an effective compound for a cutting cycle specifically?

Yes — Drostanolone Propionate is one of the most targeted androgens for cutting cycles because it preserves lean muscle under caloric restriction while contributing to a harder, more defined appearance. Its androgenic activity sustains protein synthesis during an energy deficit, and its SHBG-binding property increases free androgen availability, both of which are directly relevant to body composition goals during a cut rather than a bulk.

How is Mastelad typically structured within a 10–12 week cutting programme?

Mastelad is injected every other day (EOD) at doses ranging from 300 mg to 500 mg per week (split across EOD administrations), aligned with the propionate ester's approximately 2–3 day half-life. The cycle duration of 10–12 weeks allows gradual body-fat reduction while the compound's androgenic environment protects accrued muscle. Dosage is kept at the lower end during the first two weeks to assess individual tolerance before progression.

Which compounds pair best with Mastelad during a definition phase?

The most effective cutting stacks built around Mastelad include a testosterone propionate base (100–150 mg EOD) to maintain endocrine baseline, paired with either Oxandrolone or Stanozolol for additional hardening without aromatisation. Some advanced athletes add Trenbolone Acetate for maximum density, though this combination significantly elevates androgenic side-effect risk and is reserved for experienced users well within contest-prep protocols.

What is the advantage of the 100 mg/ml concentration for cutting-phase dosing accuracy?

At 100 mg/ml, each 0.5 ml draw delivers exactly 50 mg — a precise, insulin-syringe-compatible volume that simplifies micro-dose adjustments during caloric-deficit phases when hormonal sensitivity may shift. This concentration is practical for athletes dialling in EOD injections with a 27–29 gauge insulin syringe for smaller injection sites such as the deltoid, reducing injection discomfort during a prolonged cut.

How should Mastelad 10ml vials be stored after the first draw, and what is the shelf life once opened?

Mastelad vials should be stored at 15–25 °C, away from direct light and moisture; refrigeration is not required but is acceptable. Once the rubber stopper has been punctured, the vial remains viable for the duration of a standard cutting cycle (8–12 weeks) provided each draw uses a new sterile needle and the stopper is wiped with an isopropyl alcohol swab before every withdrawal. Inspect visually for particulate matter or discolouration before each use. (2) angle_used

Pro Choice

Driada Medical

Mastelad 100mg/ml 10ml Vial by Driada Medical

Name: Mastelad 100mg/ml 10ml Vial by Driada Medical
Brand: Driada Medical
SKU: INJ-DROP-DRI-100-005
Price: 50.00 EUR
Availability: InStock

Mastelad by Driada Medical is a pharmaceutical-grade injectable androgenic compound delivering Drostanolone Propionate at 100 mg/ml in a 10 ml multi-dose vial, purpose-built for cutting and body-definition cycles where preserving lean muscle during a caloric deficit is the primary objective. Its short-ester structure enables precise cycle management, making mid-cycle dosage adjustments straightforward without prolonged systemic carry-over. Quality is assured through the following controls: each 10 ml batch is subject to reversed-phase HPLC potency verification and a Bacterial Endotoxin Test (LAL method) prior to release.

€50.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Preserves contractile muscle tissue during sustained caloric restriction phases
Promotes a dense, dry musculature consistent with competitive definition standards
Short ester format gives rapid feedback on compound response during contest prep
Reduces SHBG binding, elevating free androgen fraction when co-administered with testosterone
10 ml multi-dose vial supplies a complete 10-week EOD cutting protocol in one container
HPLC-confirmed potency at 100 mg/ml ensures accurate dosage per injection
LAL-method endotoxin clearance verified prior to batch release for parenteral safety

Phase	dosage	Note
Cutting — Entry (Weeks 1–2)	200–300 mg/week (EOD injections of 0.5–0.75 ml)	Assess individual androgenic sensitivity; establish baseline tolerability before escalation
Cutting — Main Phase (Weeks 3–10)	300–500 mg/week (EOD injections of 0.75–1.25 ml)	Maintain consistent caloric deficit; pair with low-dose testosterone propionate base
Cutting — Peak / Contest Prep (Weeks 10–12)	400–500 mg/week (maintain EOD frequency)	Final weeks aimed at maximum hardness; reduce carbohydrate intake concurrently
Post-Cycle Transition	Final injection 5–7 days before PCT start	Propionate ester clears rapidly; begin PCT with SERMs (Nolvadex/Clomid) promptly

Key takeaways

Use Mastelad EOD to sustain androgen levels throughout a full cutting cycle.
Stack with testosterone propionate to protect muscle during caloric deficit.
Confirm lean mass retention by tracking nitrogen balance across the cut.
Leverage SHBG-binding activity to maximise free androgen availability while cutting.
Initiate PCT within one week post-cycle using the short propionate clearance window.

Drostanolone Propionate as a Cutting-Phase Androgen

Mastelad is a Drostanolone Propionate formulation designed specifically to support the body-recomposition demands of a cutting cycle — a phase characterised by reduced caloric intake, preservation of contractile muscle tissue, and progressive reduction of subcutaneous body fat. Unlike bulking compounds that drive rapid mass accumulation, Drostanolone Propionate functions as an androgenic support agent during energy restriction, counteracting the catabolic environment that a sustained deficit inevitably creates. Mastelad delivers 100 mg of active Drostanolone Propionate per millilitre across a 10 ml vial, providing a full multi-week supply within a single container.

Drostanolone Propionate exerts its anabolic-protective effect through androgen receptor binding in skeletal muscle, maintaining nitrogen retention and protein synthesis rates even when overall caloric throughput is suppressed. Critically, this compound also binds to sex hormone-binding globulin (SHBG), reducing SHBG's sequestration of free testosterone when stacked with other androgens — an effect that enhances the bioactive testosterone fraction during a cut without requiring dose escalation of the base compound. Compared to longer-ester drostanolone preparations (enanthate), the propionate variant allows faster response verification: if adverse effects emerge, clearance is measured in days rather than weeks, giving the athlete meaningful cycle control during a time-sensitive contest prep window.

How Mastelad Fits a Structured Cutting Protocol

A typical Mastelad cutting protocol spans 8–12 weeks, with injection frequency set at every other day (EOD) to maintain consistent serum androgen levels across the propionate half-life (~2–3 days, established by pharmacokinetic modelling of similar short-ester androgens). Mastelad is most commonly combined with compounds that complement its definition-enhancing properties: a low-dose testosterone propionate base sustains endocrine function, while a non-aromatising oral such as Stanozolol or Oxandrolone adds a synergistic hardening effect without additional water retention. This combination allows athletes to achieve a denser, more vascular appearance — a characteristic outcome of androgenic compounds used during low-body-fat phases, documented across competitive bodybuilding literature.

The 100 mg/ml concentration delivers a manageable injection volume per dose, suitable for administration via a 23–25 gauge needle to minimise injection site trauma during a prolonged 10–12 week cut. Each vial's bromobutyl rubber stopper and aluminium crimp seal allow repeated sterile access across multi-week cycles without compromising aseptic integrity.

Manufacturing Quality: Driada Medical's Analytical Release Process

Driada Medical subjects each Mastelad batch to a two-stage analytical release process before product is cleared for distribution. Reversed-phase HPLC quantifies Drostanolone Propionate content against a certified reference standard, confirming label-claimed concentration. A parallel Bacterial Endotoxin Test (LAL method, per Ph. Eur. 2.6.14) screens for gram-negative bacterial contaminants, enforcing parenteral safety standards consistent with EU GMP Annex 1 guidance for sterile injectable preparations. This dual-release protocol means every vial that leaves the facility carries a documented analytical fingerprint.

Usage

Visually inspect the Mastelad vial under light for clarity — any cloudiness or visible particles indicates the vial should not be used; contact the supplier.
Wipe the vial's rubber stopper with a fresh 70% isopropyl alcohol swab and allow it to air-dry for 15 seconds before inserting the needle.
Draw the calculated dose (based on your weekly cutting-phase target, divided across EOD sessions) using a 21–23 gauge drawing needle, then swap to a 23–25 gauge injection needle to reduce tissue trauma.
Inject into a well-perfused intramuscular site (glute, lateral quad, or deltoid); rotate sites across EOD sessions throughout the 10–12 week cutting cycle to prevent localised irritation.
After injection, apply gentle pressure with a sterile gauze swab — do not rub the site, as this can accelerate local dispersion and may increase discomfort at the depot site.
Log each injection date, dose, and site in a cycle diary; this record supports accurate EOD scheduling and allows pattern recognition if any site-specific sensitivity develops during the cutting phase.

Warnings

contraindications: Contraindicated in individuals with diagnosed prostate or breast carcinoma.

Not suitable for women of childbearing potential due to virilisation risk at performance doses.

Avoid use if a history of polycythaemia or significant hepatic impairment is present.

Individuals currently on anticoagulant therapy should consult a physician before use, as androgens may potentiate anticoagulant effects.

side_effects: Androgenic: accelerated scalp hair thinning in genetically predisposed individuals; increased sebaceous gland activity (acne).

Cardiovascular: suppression of HDL cholesterol during the cutting cycle; haematocrit elevation with prolonged use.

Endocrine: dose-dependent suppression of the hypothalamic-pituitary-gonadal (HPG) axis requiring structured post-cycle recovery.

Mood: heightened aggression or irritability reported at higher androgenic loads — monitor during contest-prep stress periods.

monitoring: Full blood count (FBC) and lipid panel at baseline and at mid-cycle (week 5–6) during a 10–12 week cutting phase.

Blood pressure monitoring every two weeks; androgen use can elevate systolic pressure, particularly during caloric restriction.

Haematocrit should remain below 52%; values above this threshold warrant dose reduction or cycle cessation.

pct: Begin PCT with a SERM (Nolvadex 40/40/20/20 mg or Clomid 50/50/25/25 mg, daily, across four weeks) approximately 5–7 days after the final Mastelad injection.

HCG (500 IU every other day for 10 days pre-PCT) is recommended following cycles of 10 weeks or longer to restore testicular responsiveness before SERM therapy.

Retest serum testosterone and LH/FSH at four weeks post-PCT completion to confirm HPG axis recovery.

Frequently asked questions

Is Drostanolone Propionate an effective compound for a cutting cycle specifically?: Yes — Drostanolone Propionate is one of the most targeted androgens for cutting cycles because it preserves lean muscle under caloric restriction while contributing to a harder, more defined appearance. Its androgenic activity sustains protein synthesis during an energy deficit, and its SHBG-binding property increases free androgen availability, both of which are directly relevant to body composition goals during a cut rather than a bulk.
How is Mastelad typically structured within a 10–12 week cutting programme?: Mastelad is injected every other day (EOD) at doses ranging from 300 mg to 500 mg per week (split across EOD administrations), aligned with the propionate ester's approximately 2–3 day half-life. The cycle duration of 10–12 weeks allows gradual body-fat reduction while the compound's androgenic environment protects accrued muscle. Dosage is kept at the lower end during the first two weeks to assess individual tolerance before progression.
Which compounds pair best with Mastelad during a definition phase?: The most effective cutting stacks built around Mastelad include a testosterone propionate base (100–150 mg EOD) to maintain endocrine baseline, paired with either Oxandrolone or Stanozolol for additional hardening without aromatisation. Some advanced athletes add Trenbolone Acetate for maximum density, though this combination significantly elevates androgenic side-effect risk and is reserved for experienced users well within contest-prep protocols.
What is the advantage of the 100 mg/ml concentration for cutting-phase dosing accuracy?: At 100 mg/ml, each 0.5 ml draw delivers exactly 50 mg — a precise, insulin-syringe-compatible volume that simplifies micro-dose adjustments during caloric-deficit phases when hormonal sensitivity may shift. This concentration is practical for athletes dialling in EOD injections with a 27–29 gauge insulin syringe for smaller injection sites such as the deltoid, reducing injection discomfort during a prolonged cut.
How should Mastelad 10ml vials be stored after the first draw, and what is the shelf life once opened?: Mastelad vials should be stored at 15–25 °C, away from direct light and moisture; refrigeration is not required but is acceptable. Once the rubber stopper has been punctured, the vial remains viable for the duration of a standard cutting cycle (8–12 weeks) provided each draw uses a new sterile needle and the stopper is wiped with an isopropyl alcohol swab before every withdrawal. Inspect visually for particulate matter or discolouration before each use. (2) angle_used

Manufacturer

Driada Medical's product portfolio is structured around therapeutic category focus rather than broad-spectrum ingredient coverage — and within its injectable androgen line, Mastelad occupies a defined slot: the brand's dedicated Drostanolone Propionate offering, positioned alongside other short-ester compounds that share a common analytical release framework. This portfolio logic means Mastelad is not incidental to the brand's catalogue but sits within a deliberate product architecture where each entry corresponds to a specific ester class and clinical-use profile. Across that architecture, Driada Medical applies a consistent tier of documentary evidence: reversed-phase HPLC assay confirming active-ingredient concentration against certified reference material, and a Bacterial Endotoxin Test conducted to Ph. Eur. 2.6.14 standards before any batch is released. What differentiates Mastelad's place in the portfolio specifically is its alignment with the short-ester, high-frequency-dosing segment — a niche Driada Medical has deliberately equipped with appropriate pack sizes and concentration choices rather than defaulting to a one-size catalogue approach.

Product details

Brand	Driada Medical
Active ingredient	drostanolone propionate
Also known as	Masteron, Drolban, Drostanolone Propionate, Mastelad, Driada Medical Masteron
Strength	100 mg
Form	Vial
Pack size	1 piece
Item number	INJ-DROP-DRI-100-005

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Optimal Dosage

Propha-Masteron 100mg/ml 10ml Vial by Beligas Pharmaceuticals

Propha-Masteron is an oil-based injectable solution delivering Drostanolone Propionate at 100mg/ml, distinguished by its capacity to bypass hepatic first-pass metabolism entirely — a pharmacokinetic advantage that oral androgen compounds cannot replicate. Each 10ml multi-dose vial provides a full cycle's supply of pharmaceutical-grade active, with systemic absorption occurring directly through intramuscular tissue into the bloodstream. Quality assurance is built into every lot: HPLC potency verification, LAL endotoxin screening, and GMP-certified filling suites are standard — not optional — at Beligas Pharmaceuticals.

€46.00

Masten-100 100mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Fast Acting

Masten-100 100mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Masten-100 is a fast-acting injectable androgenic compound delivering Drostanolone Propionate at 100mg/ml in single-dose 1ml ampoules, specifically engineered for rapid tissue uptake and measurable efficacy within the first days of administration. The propionate ester's short carbon chain enables peak plasma concentrations to establish quickly — typically within 24–48 hours of the first injection — making it one of the fastest-onset drostanolone formulations available. Every lot is released only after HPLC potency confirmation and LAL endotoxin screening; sterility is assured via Ph. Eur. 2.6.1-compliant testing conducted at BM Pharmaceuticals' GMP-certified facility.

€47.00

High Concentration

MasterTrex 150mg/ml 10ml Vial by Concentrex Labs

MasterTrex is a high-concentration Drostanolone Propionate injectable, formulated at 150 mg/ml in a 10 ml multi-dose vial and engineered for athletes who demand precise, schedule-driven injection timing across their cutting or pre-contest phase. At 150 mg/ml, each draw delivers a clinically meaningful dose in a compact volume, making every-other-day or every-third-day scheduling straightforward without excess injection site load. Quality is locked in at batch level: HPLC-quantified potency verification and LAL endotoxin testing are completed before any MasterTrex vial leaves the Concentrex Labs facility.

€50.00

Brand Quality

Masteron 100 100mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma Masteron 100 is a drostanolone propionate injectable solution at 100mg/ml in a 10ml multi-dose vial, specifically suited to frontloading protocols that compress the time-to-steady-state window at the opening of a cycle. Because the propionate ester releases active drostanolone within a short half-life of approximately 2–3 days, calculated loading doses can bring circulating androgen levels to the target therapeutic range within the first 72 hours rather than waiting the usual week or more. Dragon-Pharma batch-releases every vial only after HPLC potency verification and LAL endotoxin clearance — two independent quality gates applied sequentially before product leaves the facility.

€42.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00